DNA origami vaccine (DoriVac) nanoparticles improve both humoral and cellular immune responses to infectious diseases.

ABSTRACT: Current SARS-CoV-2 vaccines have demonstrated robust induction of neutralizing antibodies and CD4⁺ T cell activation, however CD8⁺ responses are variable, and the duration of immunity and protection against variants are limited. Here we repurposed our DNA origami vaccine nanotechnology, DoriVac, for targeting infectious viruses, namely SARS-CoV-2, HIV, and Ebola. The DNA origami nanoparticle, conjugated with infectious-disease-specific heptad repeat 2 (HR2) peptides, which act as highly conserved antigens, and CpG adjuvant at precise nanoscale spacing, induced neutralizing antibodies, Th1 CD4⁺ T cells, and CD8⁺ T cells in naïve mice, with significant improvement over a bolus control. Pre-clinical studies using lymph-node-on-a-chip systems validat

SUBMITTER: Zeng YC 

PROVIDER: S-EPMC10802255 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature